Lavinia Domenici

Lavinia Domenici

Auto-generated profile, based on publicly available information

Lavinia Domenici

Division of Obstetrics and Gynecology, Azienda Ospedaliera Universitaria Pisana, University of Pisa, 56126 Pisa, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2010 in Gynecological Endocrinology
Verified
Journal Article
Closed access
PDF file
AGAngiolo Gadducci
Angiolo Gadducci
CBCecilia Barsotti
Cecilia Barsotti
SCStefania Cosio
Stefania Cosio
LDLavinia Domenici
Lavinia Domenici
AGAndrea Riccardo Genazzani
Andrea Riccardo Genazzani
High-risk human papillomaviruses (HPVs) are involved in the etiopathogenesis of cervical intraepithelial neoplasia (CIN) and cervical cancer. After taking HPV into account, smoking habit appears to be the most significant environmental risk factor, and the risk of this malignancy increases significantly with intensity and duration of smoking. Women with human immunodeficiency virus (HIV) infection experience a higher incidence of CIN and invasive cervical cancer. Among HIV+ women, the highly active antiretroviral therapy increases the regression rate of CIN, but the majority of these lesions do not regress to normal. As far as oral contraceptives (OCs), a systematic review of 28 studies found that, compared with never pill users, the relative risk (RR) of cervical cancer increased with increasing duration of OC use. The results were similar for squamous cell carcinoma and adenocarcinoma, and the RRs decreased after pill discontinuation. However, by weighing risks and benefits, the World Health Organization does not recommend any change in OC practice. There is no correlation between hormone replacement therapy and cervical cancer. Experimental data have shown that estradiol and progesterone can modulate the host immune response to HPV16. Prophylactic vaccination in conjunction with cervical screening is the best prevention strategy for cervical cancer.

1 July 2014 in OncoTargets and Therapy
Verified
Journal Article
Open access
Claudia MarchettiClaudia Marchetti
Claudia Marchetti
MGMargherita Giorgini
Margherita Giorgini
CMCaterina De Medici
Caterina De Medici
IPInnocenza Palaia
Innocenza Palaia
RIRoberta Iadarola
Roberta Iadarola
FTFederica Tomao
Federica Tomao
Ovarian cancer is the most common cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease; although chemotherapeutic advances have improved progression-free survival, conventional treatments offer limited results in terms of long-term responses and survival. Research has recently focused on targeted therapies, which represent a new, promising therapeutic approach, aimed to maximize tumor kill and minimize toxicity. Besides antiangiogenetic agents and poly (ADP-ribose) polymerase inhibitors, the folate, with its membrane-bound receptor, is currently one of the most investigated alternatives. In particular, folate receptor (FR) has been shown to be frequently overexpressed on the surface of almost all epithelial ovarian cancers, making this receptor an excellent tumor-associated antigen. There are two basic strategies to targeting FRs with therapeutic intent: the first is based on anti-FR antibody (ie, farletuzumab) and the second is based on folate–chemotherapy conjugates (ie, vintafolide/etarfolatide). Both strategies have been investigated in Phase III clinical trials. The aim of this review is to analyze the research regarding the activity of these promising anti-FR agents in patients affected by ovarian cancer, including anti-FR antibodies and folate–chemotherapy conjugates.

5 January 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
EPEttore Palma
Ettore Palma
NRNadia Recine
Nadia Recine
LDLavinia Domenici
Lavinia Domenici
MGMargherita Giorgini
Margherita Giorgini
APALESSANDRA PIERANGELI
ALESSANDRA PIERANGELI
PPPierluigi Benedetti Panici
Pierluigi Benedetti Panici
Over recent years, a growing interest has developed in microbiota and in the concept of maintaining a special balance between Lactobacillus and other bacteria species in order to promote women’s well-being. The aim of our study was to confirm that vaginal Lactobacilli long-lasting implementation in women with HPV-infections and concomitant bacterial vaginosis or vaginitis might be able to help in solving the viral infection, by re-establishing the original eubiosis. A total of 117 women affected by bacterial vaginosis or vaginitis with concomitant HPV-infections were enrolled at Department of Gynecological Obstetrics and Urological Sciences, La Sapienza University, Rome, Italy between February 2015 and March 2016. Women were randomized in two groups, standard treatment (metronidazole 500 mg twice a day for 7 days or fluconazole 150 mg orally once a day for 2 consecutive days) plus short-term (3 months) vaginal Lactobacillus implementation (group 1, short probiotics treatment protocol group, n = 60) versus the same standard treatment plus long-lasting (6 months) vaginal Lactobacillus rhamnosus BMX 54 administration (group 2, treatment group, n = 57). After a median follow up of 14 months (range 9–30 months) the chance to solve HPV-related cytological anomalies was twice higher in probiotic long-term users (group 2) versus short probiotics implementation group (group 1) (79.4% vs 37.5%, p = 0.041). Moreover, a total HPV-clearance was shown in 11.6% of short schedule probiotics implementation patients compared to a percentage of 31.2% in vaginal Lactobacilli long term users (p = 0.044), assessed as negative HPV-DNA test documented at the end of the study period. The consistent percentage of clearance of PAP-smear abnormalities and HPV-clearance obtained in long-term treatment group has been interestingly high and encouraging. Obviously, larger and randomized studies are warranted to confirm these encouraging results, but we believe that eubiosis re-establishment is the key to tackle effectively even HPV-infection. Retrospectively registered on PRS NCT03372395 (12/12/2017).

1 June 2016 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
Glenda Giorgia CaputoGlenda Giorgia Caputo
Glenda Giorgia Caputo
AMAlberto Marchetti
Alberto Marchetti
EPEdoardo Dalla Pozza
Edoardo Dalla Pozza
EVEnrico Vigato
Enrico Vigato
LDLavinia Domenici
Lavinia Domenici
MGMaurizio Governa
Maurizio Governa
Summary: Skin-reduction mastectomy with prepectoral implant reconstruction is a novel technique for immediate breast reconstruction, with subcutaneous implant placement in patients eligible for skin-reducing mastectomy. Implants were placed above the pectoralis muscles in a compound pocket made by a dermal flap and acellular dermal matrix. The procedure was performed on 33 breasts in 27 selected patients. In three cases, there was skin ischemia; in one case, it healed spontaneously; and in two patients, a surgical necrosectomy and primary closure were needed. No implant loss occurred. This new technique proved to be a useful alternative, with good cosmetic results, in selected patients requiring mastectomy. These preliminary results need to be confirmed by long-term and comparative studies. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

5 July 2015 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
NRNadia Recine
Nadia Recine
EPEttore Palma
Ettore Palma
LDLavinia Domenici
Lavinia Domenici
MGMargherita Giorgini
Margherita Giorgini
LILudovica Imperiale
Ludovica Imperiale
PPPierluigi Benedetti Panici
Pierluigi Benedetti Panici

1 August 2021 in Clinical Breast Cancer
Verified
Journal Article
Closed access
Glenda Giorgia CaputoGlenda Giorgia Caputo
Glenda Giorgia Caputo
Nicola ZingarettiNicola Zingaretti
Nicola Zingaretti
IKIoanna Kiprianidis
Ioanna Kiprianidis
CZChiara Zanfisi
Chiara Zanfisi
LDLavinia Domenici
Lavinia Domenici
MGMaurizio Governa
Maurizio Governa